Skip to content
Business Company News, Information Technology

How ‘Omega’ is a quantum leap for Australia – interview available

PsiQuantum < 1 mins read
  • Media:

PsiQuantum, the company building the world’s first utility-scale quantum computer in Brisbane, has just announced a significant scientific milestone: Omega – a manufacturable chipset that will take quantum computing out of the lab and into the real world. 

 

The chipset contains all the advanced components required to build the quantum computer planned for Brisbane. 

 

The Omega chipset is featured in a paper published today in Nature.

 

The Nature paper is extremely significant for Australia in particular, having invested heavily in PsiQuantum’s photonic approach, the roots of which stem from research at Australian universities. 

 

Geoff Pryde, PsiQuantum Australia’s Chief Technical Director, is available for interview today about why this represents such a big moment for quantum computing – and for Australia. 

 

Geoff can talk about: 

  • What today’s announcement means for Australia’s effort to build the world’s first useful quantum computer in Brisbane 

  • How the Omega chipset, designed by PsiQuantum and manufactured by GlobalFoundries, contains all of the advanced components required to build the utility-scale quantum computer in Brisbane

  • His experience researching photonics with PsiQuantum co-founder Jeremy O’Brien at the University of Queensland in the early 2000s and how this created a pathway to today’s announcement

  • Why PsiQuantum’s announcement today is different from other recent quantum computing announcements 

 

 


About us:

PsiQuantum’s full global announcement
Image library


Contact details:

Anil Lambert 0416 426 722 / anil@hortonadvisory.com.au

Media

Images
OmegaOmega

Omega3.jpg

Omega
Download media

More from this category

  • Information Technology
  • 01/04/2025
  • 12:11
Picus Security

Picus Security Announces Recognition in Gartner® Market Guide for Adversarial Exposure Validation

Picus Security strives to empower offensive and defensive security teams working to validate threat exposures against attack scenarios and techniques.SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- Picus Security, the leading security validation company, today announced that it has been named a Representative Vendor in the Gartner® Market Guide for Adversarial Exposure Validation (AEV). The AEV category includes technology that validates vulnerabilities and identifies techniques that allow adversaries to exploit an organization. This research helps security and risk management leaders understand the key use cases of adversarial exposure validation and navigate the AEV solution market.The AEV market category brings breach…

  • Biotechnology, Business Company News
  • 01/04/2025
  • 11:13
Optiscan Imaging Limited (ASX:OIL)

Optiscan Imaging (ASX:OIL) Announces New CFO & Other Executive Appointments

These senior executive team changes mean Optiscan is now better resourced to implement its transformation plan and future-focussed priorities. Highlights •Optiscan’s current Finance Manager, Mr Darius Ooi, has been promoted to the Chief Financial Officer role, and will now lead the Corporate team. • Ms Belinda Williamson has been appointed as Chief Commercial Officer, and will head Optiscan’s Customer team and lead the Company’s efforts to derive value from its expanding commercial opportunities. • Ms Jessica Ward has been appointed Optiscan’s US-based Director of Clinical & Regulatory Affairs, and will manage the Company’s burgeoning clinical and regulatory portfolios and lead…

  • Biotechnology, Business Company News
  • 01/04/2025
  • 10:03
Jane Morgan Management

BlinkLab Limited Surpasses Key Milestone in Pivotal US Autism Diagnostic Trial

Perth, Australia – 1 April 2025 | BlinkLab Limited (ASX: BB1) (“BlinkLab” or the “Company”) is pleased to announce it has successfully recruited 54 children as participants, surpassing the halfway point of the initial 100-patient phase of its pivotal U.S. clinical trial to validate the Company’s AI-powered smartphone-based autism diagnostic tool. The trial is part of a regulatory pathway for FDA 510(k) clearance and has been designed to demonstrate the accuracy, accessibility, and scalability of the BlinkLab Dx 1 product as a diagnostic aid in identifying autism and other developmental conditions in children. Highlights 54 children are now recruited in…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.